Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mckesson Corp filings on SEC EDGAR ↗
Mckesson EVP, CIO and CTO Francisco Fraga Sells $717K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 650 shares of Mckesson Corp at $1,102.96 a share, worth $717K in total on Nov 5, 2026. Shares held after the trade: 4,414 (-12.8%).
McKesson delivered a strong Q2 FY2027, beating internal expectations and raising full-year EPS guidance, driven by specialty distribution, GLP-1 volume, and strategic acquisitions in oncology and home infusion.
Mckesson EVP, CIO and CTO Francisco Fraga Sells $630K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 600 shares of Mckesson Corp at $1,050.00 a share, worth $630K in total on Nov 4, 2026. Shares held after the trade: 5,064 (-10.6%).
For the three months ended September 30, 2026, McKesson reported revenues of $111.0 billion, a 7.6% increase year-over-year, and net income attributable to the corporation of $1.2 billion. The company's balance sheet shows a significant increase in total assets to $92.3 billion, primarily driven by higher cash and inventory levels, while stockholders' deficit widened to $4.0 billion.
McKesson reported second quarter fiscal 2027 consolidated revenues of $111.0 billion, an 8% increase year-over-year, and raised its full-year adjusted EPS guidance. The results were driven by strong operational growth in the North American Pharmaceutical and Oncology & Multispecialty segments.
Term
Q2 2027
“McKesson delivered another quarter of strong results, reflecting operational strength in our core business segments and disciplined execution across the enterprise.”
Mckesson EVP, CIO and CTO Francisco Fraga Sells $797K of Stock
Francisco Fraga, EVP, CIO and CTO, sold 800 shares of Mckesson Corp at $995.80 a share, worth $797K in total on Oct 15, 2026. Shares held after the trade: 5,423 (-12.9%).
Mckesson Signs $5.8B M&A Deal with Option Care Health, Inc.
McKesson Corporation and Clayton, Dubilier & Rice (CD&R) have entered into a definitive agreement to acquire Option Care Health for $32.05 per share, representing a total enterprise value of approximately $5.8 billion. Upon closing, CD&R will hold a majority stake while McKesson will hold a minority interest in the home and alternate site infusion services provider. The deal aligns with McKesson's strategy to expand access to innovative therapies in lower-cost community and home settings.